Suppr超能文献

浸润肿瘤的肿瘤抗原特异性CD8 T细胞表达高水平的PD-1且功能受损。

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

作者信息

Ahmadzadeh Mojgan, Johnson Laura A, Heemskerk Bianca, Wunderlich John R, Dudley Mark E, White Donald E, Rosenberg Steven A

机构信息

Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.

出版信息

Blood. 2009 Aug 20;114(8):1537-44. doi: 10.1182/blood-2008-12-195792. Epub 2009 May 7.

Abstract

Tumor antigen-specific T cells are found within melanomas, yet tumors continue to grow. Although the tumor microenvironment is thought to influence the suppression of tumor-reactive T cells, the underlying mechanisms for this T-cell dysfunction are not clear. Here, we report that the majority of tumor infiltrating T lymphocytes (TIL), including MART-1/Melan-A melanoma antigen-specific CD8 T cells, predominantly expressed PD-1, in contrast to T cells in normal tissues and peripheral blood T lymphocytes (PBL). PD-1(+) TIL expressed CTLA-4 and Ki-67, markers that were not expressed by PD-1(-) TIL and T cells in the normal tissues and PBL. Moreover, PD-1(+) TIL were primarily HLA-DR(+) and CD127(-), in contrast to PD-1(-) TIL. Effector cytokine production by PD-1(+) TIL was impaired compared with PD-1(-) TIL and PBL. Collectively, the phenotypic and functional characterizations of TIL revealed a significantly higher frequency and level of PD-1 expression on TIL compared with normal tissue T-cell infiltrates and PBL, and PD-1 expression correlated with an exhausted phenotype and impaired effector function. These findings suggest that the tumor microenvironment can lead to up-regulation of PD-1 on tumor-reactive T cells and contribute to impaired antitumor immune responses.

摘要

在黑色素瘤中可发现肿瘤抗原特异性T细胞,但肿瘤仍持续生长。尽管肿瘤微环境被认为会影响肿瘤反应性T细胞的抑制作用,但其导致T细胞功能障碍的潜在机制尚不清楚。在此,我们报告,与正常组织中的T细胞和外周血T淋巴细胞(PBL)相比,包括MART-1/黑色素A黑色素瘤抗原特异性CD8 T细胞在内的大多数肿瘤浸润性T淋巴细胞(TIL)主要表达程序性死亡受体1(PD-1)。与正常组织和PBL中的PD-1(-)T细胞和T细胞不同,PD-1(+)TIL表达细胞毒性T淋巴细胞相关抗原4(CTLA-4)和Ki-67,而PD-1(-)TIL以及正常组织和PBL中的T细胞不表达这些标志物。此外,与PD-1(-)TIL相比,PD-1(+)TIL主要为人类白细胞抗原DR(HLA-DR)阳性和CD127阴性。与PD-1(-)TIL和PBL相比,PD-1(+)TIL产生效应细胞因子的能力受损。总体而言,TIL的表型和功能特征显示,与正常组织T细胞浸润和PBL相比,TIL上PD-1表达的频率和水平显著更高,且PD-1表达与耗竭表型和效应功能受损相关。这些发现表明,肿瘤微环境可导致肿瘤反应性T细胞上PD-1上调,并导致抗肿瘤免疫反应受损。

相似文献

1
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.
Blood. 2009 Aug 20;114(8):1537-44. doi: 10.1182/blood-2008-12-195792. Epub 2009 May 7.
2
PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.
Cancer Immunol Res. 2015 Aug;3(8):926-35. doi: 10.1158/2326-6066.CIR-14-0239. Epub 2015 May 8.
3
T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
Clin Cancer Res. 2011 Sep 1;17(17):5736-47. doi: 10.1158/1078-0432.CCR-11-0230. Epub 2011 Jul 12.
4
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Gastroenterology. 2017 Oct;153(4):1107-1119.e10. doi: 10.1053/j.gastro.2017.06.017. Epub 2017 Jun 23.
6
Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells.
J Immunother. 2010 Nov-Dec;33(9):956-64. doi: 10.1097/CJI.0b013e3181fad2b0.
8
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80. doi: 10.1073/pnas.1003345107. Epub 2010 Apr 12.
10

引用本文的文献

1
Dual regulation of gastrointestinal tumor progression by the IFN-γ/STAT1 pathway and prospects for targeted therapy.
Front Oncol. 2025 Aug 20;15:1598170. doi: 10.3389/fonc.2025.1598170. eCollection 2025.
3
Chronic antigen stimulation in melanoma induces T cell exhaustion and limits efficacy of T cell bispecific therapies.
Oncoimmunology. 2025 Dec;14(1):2526444. doi: 10.1080/2162402X.2025.2526444. Epub 2025 Aug 26.
4
Longitudinal Monitoring of T cell Dynamics in Metastatic Breast Cancer via a Remote Diagnostic Implant.
Immunomedicine. 2024 Dec;4(2). doi: 10.1002/imed.70000. Epub 2025 Jun 9.
5
Advances in PD-1/PD-L1 pathway inhibitors in the treatment of thyroid cancer: mechanisms and clinical therapeutic perspectives.
Front Immunol. 2025 Aug 8;16:1643421. doi: 10.3389/fimmu.2025.1643421. eCollection 2025.
6
Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM.
Front Immunol. 2025 Jul 31;16:1579925. doi: 10.3389/fimmu.2025.1579925. eCollection 2025.
8
Epstein-Barr Virus (EBV)-Positive Diffuse Large B-Cell Lymphoma in a Young Patient: A Difficult Diagnosis.
Cureus. 2025 Jun 17;17(6):e86254. doi: 10.7759/cureus.86254. eCollection 2025 Jun.
9
Tumor infiltration therapy: from FDA approval to next-generation approaches.
Clin Exp Med. 2025 Jul 18;25(1):254. doi: 10.1007/s10238-025-01574-6.
10
Monitoring pembrolizumab response in patients with metastatic non-small cell lung cancer using circulating tumour DNA and circulating tumour cells.
Transl Lung Cancer Res. 2025 Jun 30;14(6):1945-1960. doi: 10.21037/tlcr-2024-1095. Epub 2025 Jun 26.

本文引用的文献

2
3
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity.
Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8061-6. doi: 10.1073/pnas.0710929105. Epub 2008 Jun 3.
4
PD-1 and its ligands in tolerance and immunity.
Annu Rev Immunol. 2008;26:677-704. doi: 10.1146/annurev.immunol.26.021607.090331.
5
Molecular signature of CD8+ T cell exhaustion during chronic viral infection.
Immunity. 2007 Oct;27(4):670-84. doi: 10.1016/j.immuni.2007.09.006. Epub 2007 Oct 18.
9
Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy.
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):709s-715s. doi: 10.1158/1078-0432.CCR-06-1868.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验